@Article{Cisoń2023,
journal="Dermatology Review/Przegląd Dermatologiczny",
issn="0033-2526",
volume="110",
number="6",
year="2023",
title="Use of rituximab in the treatment of pemphigus vulgaris 
in a juvenile patient",
abstract="Introduction: Pemphigus vulgaris is a chronic autoimmune blistering  disorder characterised by the production of autoantibodies against  desmogleins, resulting in intraepithelial blister formation. Despite  advancements in treatment options, some patients experience disease  progression and an inadequate response to conventional therapies. Rituximab,  a monoclonal chimeric antibody targeting CD20 on B-cells,  has shown promise as an alternative therapeutic option.  Case report: In this case report, we present the management of a  14-year-old child with pemphigus vulgaris who exhibited disease progression  despite conventional treatment modalities. The patient was  administered rituximab therapy, resulting in significant clinical improvement  and disease control.  Conclusions: The utilisation of rituximab as an adjunct or alternative  therapy in refractory pemphigus cases offers a valuable treatment  option. Further studies and long-term follow-up are necessary to determine  the optimal dosing regimen and evaluate the safety and efficacy  of rituximab in paediatric pemphigus patients.",
author="Cisoń, Hanna Róża
and Baran, Wojciech
and Białynicki-Birula, Rafał",
pages="694--697",
doi="10.5114/dr.2023.135677",
url="http://dx.doi.org/10.5114/dr.2023.135677"
}